Search clinical trials for: Roxadustat

Total 53 results

Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Japan
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Chronic Kidney Diseases | Renal Anemia

China
FibroGen
AstraZeneca

Withdrawn

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia

United States
Mao Jianhua

Recruiting

Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
Astellas Pharma Global Development, Inc.
FibroGen

Completed

A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects

Healthy Adult Subjects

Germany
Astellas Pharma Inc

Completed

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Anemia | Hemodialysis | Renal Impairment

Japan
Ruijin Hospital

Recruiting

Study of Roxadustat in the Treatment of Acute Myocardial Infarction (ROXAMI)

ST Elevation Myocardial Infarction

China
Astellas Pharma Inc
FibroGen

Completed

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Hemodialysis Patients With Renal Anemia

Japan
Peking Union Medical College Hospital
Beijing Hospital

Recruiting

Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

Coronary Artery Bypass

China
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Shenzhen Second People's Hospital

Recruiting

Roxadustat for Anemia in Patients With CKD

Anemia of Chronic Kidney Disease

China
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
Peking University First Hospital
Beijing Haidian Hospital; Beijing Hospital of Traditional Chinese Medicine

Completed

Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients

Renal Anemia

China
Peking Union Medical College Hospital

Not yet recruiting

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Myelodysplastic Syndromes

China
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Anemia Associated With End Stage Renal Disease (ESRD)

United States
AstraZeneca
FibroGen

Completed

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Anemia

United States, Spain, Thailand, Vietnam, Turkey, Canada, Korea, Republic of, Brazil, Hungary, India, Peru, Philippines, Taiwan, Germany, Slovakia, Russian Federation, Ukraine, Czechia, Poland, Argentina, Bulgaria, Colombia, Malaysia, ... and more
FibroGen

Completed

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

CKD Anemia in Dialysis Participants

China
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
AstraZeneca
Parexel

Completed

A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)

Anemia of Chronic Kidney Disease

China
Region Stockholm

Not yet recruiting

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (FOXTROT)

Diabetes Complications | Diabetes; Nephropathy (Manifestation)

Sweden
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
Astellas Pharma Inc

Completed

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Anemia | Chronic Kidney Disease

United States
Trius Therapeutics LLC

Completed

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Bacterial Infection

United States
Trius Therapeutics LLC

Completed

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Bacterial Infection
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
AstraZeneca
FibroGen

Completed

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

Anemia

United States, Thailand, Vietnam, Canada, Peru, Philippines, Slovakia, Poland, Russian Federation, Ukraine, Czechia, Spain, Hungary, Australia, Bulgaria, India, Mexico, Sweden
Peking Union Medical College Hospital

Not yet recruiting

A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

Myelodysplastic Syndromes
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (ASPEN)

Anemia Associated With End Stage Renal Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Anemia | End Stage Renal Disease

United States
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Anemia | Chronic Kidney Disease

United States, Puerto Rico
China-Japan Friendship Hospital

Not yet recruiting

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Heart Failure | Chronic Kidney Diseases | Anemia
FibroGen

Completed

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Chemotherapy Induced Anemia

China
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Spain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Anemia | End Stage Renal Disease | Chronic Kidney Disease

Puerto Rico, United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Alexandria University

Recruiting

Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Anemia in Dialysis-dependent CKD Patients

Egypt
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (Dolomites)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain and more
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees)

Anemia | End Stage Renal Disease (ESRD)

Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Russian Federation, Serbia, Spain, United Kingdom, Belgium, France, Georgia, Italy, Portugal, Romania, Slovakia

Search clinical trials for: Roxadustat

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations